Overview
IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a synthetic, modified analog of human insulin-like growth factor 1 (IGF-1). The modification consists of replacing the glutamic acid at position 3 with an arginine (R3) and adding a 13-amino acid N-terminal extension peptide. These changes reduce binding to IGF-binding proteins (IGFBPs), resulting in a significantly longer half-life and greater bioavailability compared to native IGF-1.
Native IGF-1 is a 70-amino acid peptide hormone primarily produced by the liver in response to growth hormone (GH) stimulation. It mediates many of GH's anabolic effects including muscle growth, bone development, and tissue repair. However, over 98% of circulating IGF-1 is bound to IGFBPs (primarily IGFBP-3), which sequester the hormone and limit its biological activity. IGF-1 LR3's reduced IGFBP affinity means a much larger proportion remains free and bioactive.
IGF-1 LR3 has become one of the most widely used peptides in the bodybuilding and performance enhancement community due to its potent anabolic effects. It promotes muscle hyperplasia (new muscle fiber formation), enhances protein synthesis, improves nutrient partitioning, and has anti-catabolic properties. However, it carries significant risks including hypoglycemia, organ growth, and potential cancer promotion.
This guide provides a research-based analysis of IGF-1 LR3, its mechanism, efficacy evidence, safety concerns, and critical risk-benefit considerations.
Quick facts
- Mechanism
- Modified IGF-1 with enhanced bioavailability for anabolic effects
- Primary use
- Muscle Growth & Tissue Repair
- Evidence
- moderate
- FDA
- Not approved
- Route
- Subcutaneous or intramuscular injection
- Typical results
- Enhanced muscle protein synthesis and recovery; visible body composition changes in 4–8 weeks
Chemical information
IGF-1 LR3 is an 83-amino acid protein with a molecular mass of approximately 9,111 g/mol. It differs from native IGF-1 (70 amino acids) by the addition of 13 amino acids at the N-terminus and substitution of Arg for Glu at position 3. These modifications reduce IGFBP binding affinity by >100-fold while preserving full IGF-1R activation capacity.
How IGF-1 LR3 works
IGF-1 LR3 exerts its biological effects by binding to the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor expressed on virtually all human cell types. Upon ligand binding, IGF-1R undergoes autophosphorylation and activates two major intracellular signaling cascades: the PI3K/Akt/mTOR pathway (promoting protein synthesis and cell survival) and the Ras/MAPK pathway (driving cell proliferation and differentiation).
The PI3K/Akt/mTOR pathway is the primary anabolic signaling cascade activated by IGF-1 LR3. Akt phosphorylation leads to mTOR complex 1 (mTORC1) activation, which directly stimulates ribosomal protein synthesis through p70S6K and 4E-BP1 phosphorylation. Simultaneously, Akt suppresses muscle protein degradation by phosphorylating and inactivating FoxO transcription factors that would otherwise upregulate the ubiquitin-proteasome and autophagy-lysosome proteolytic pathways.
A unique property of IGF-1 that distinguishes it from other anabolic agents is its ability to promote satellite cell proliferation and differentiation, leading to muscle fiber hyperplasia (formation of new muscle fibers) in addition to hypertrophy (enlargement of existing fibers). This hyperplastic effect has been demonstrated in animal studies and is believed to contribute to permanent increases in muscle fiber number.
The reduced IGFBP binding of IGF-1 LR3 is a double-edged sword: while it dramatically increases bioactivity, it also means that normal regulatory mechanisms cannot buffer IGF-1 signaling. This creates a higher risk of off-target effects including stimulation of cell growth in non-muscle tissues, enhanced insulin-like metabolic effects (hypoglycemia risk), and potential promotion of neoplastic cell growth.
- PI3K/Akt/mTOR activation: Directly stimulates muscle protein synthesis through ribosomal machinery
- FoxO inhibition: Suppresses muscle protein degradation pathways (anti-catabolic)
- Satellite cell activation: Promotes muscle stem cell proliferation for fiber hyperplasia
- Reduced IGFBP binding: 3x longer half-life and greater free bioactive fraction than native IGF-1
- Nutrient partitioning: Drives glucose and amino acids preferentially into muscle tissue
- Anti-apoptotic effects: Promotes cell survival through Akt-mediated BAD phosphorylation
Pharmacokinetics
Pharmacokinetic parameters based on research studies comparing IGF-1 LR3 to native IGF-1.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (SC/IM) | High (~80%+) | Excellent absorption from injection sites |
| Half-life | 20–30 hours | ~3x longer than native IGF-1 (8–12 hrs) |
| IGFBP binding | Markedly reduced | Much higher free (bioactive) fraction |
| IGF-1R affinity | Equal to native IGF-1 | Full receptor activation despite structural changes |
| Metabolism | Proteolytic degradation | Standard peptide clearance pathways |
| Onset of effects | Minutes (metabolic); weeks (anabolic) | Hypoglycemia risk is immediate; muscle effects are gradual |
Dosing & administration
IGF-1 LR3 is typically used at doses of 20–100 mcg per day via subcutaneous or intramuscular injection. Bodybuilders commonly use 40–80 mcg/day, split into bilateral injections into target muscle groups (site-specific enhancement). Cycles typically last 4–6 weeks, with most protocols recommending no longer than 50 days of continuous use.
Due to the potent insulin-like metabolic effects, IGF-1 LR3 should always be administered with or immediately before a carbohydrate-containing meal to mitigate hypoglycemia risk. Some users co-administer fast-acting carbohydrates (30–50g) immediately post-injection as a safety measure.
It is absolutely critical to note that IGF-1 LR3 is not FDA-approved for any human use and carries significant safety risks. The narrow therapeutic window between anabolic effects and dangerous hypoglycemia or organ growth makes this one of the highest-risk peptides available. Medical supervision is strongly recommended.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
IGF-1 LR3 carries substantial safety risks that differentiate it from many other peptides. Hypoglycemia is an immediate and potentially life-threatening concern. Long-term use has been associated with organ growth (particularly intestinal and cardiac), and epidemiological data consistently links elevated IGF-1 levels with increased cancer risk. This compound should only be used with full awareness of these risks and ideally under medical supervision.
Common
- • Hypoglycemia (can be severe; most dangerous side effect)
- • Joint pain and swelling
- • Injection site pain and swelling
- • Headache
- • Nausea
- • Lethargy and fatigue
Serious / potential risks
- • Severe hypoglycemia (potentially life-threatening)
- • Organ enlargement (intestines, heart) with chronic use
- • Increased cancer risk (IGF-1 promotes cell proliferation)
- • Jaw and extremity growth (acromegaly-like effects)
- • Cardiomegaly with prolonged use
- • Peripheral neuropathy
Drug interactions
Important interactions due to IGF-1 LR3's potent metabolic effects.
| Medication | Interaction | Recommendation |
|---|---|---|
| Insulin | Severe additive hypoglycemia risk | Extremely dangerous combination; avoid |
| Sulfonylureas/Meglitinides | Both lower blood glucose | Significant hypoglycemia risk; avoid combination |
| Growth hormone | GH stimulates endogenous IGF-1; additive effects | Commonly combined in performance use; increases all risks |
| Beta-blockers | May mask hypoglycemia symptoms (tachycardia, tremor) | Avoid; could delay recognition of dangerous hypoglycemia |
| Anticoagulants | IGF-1 may affect platelet function | Monitor coagulation parameters |
Storage & handling
Lyophilized Powder
- • Store at -20°C for maximum stability
- • Protect from light exposure
- • Do not repeatedly freeze-thaw
- • Stable for 2+ years if properly stored
Reconstituted Solution
- • Reconstitute with bacteriostatic water or acetic acid (0.6%)
- • Store at 2–8°C after reconstitution
- • Use within 30 days of reconstitution
- • Avoid contamination; use sterile technique
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide suppliers | $40–$100 per mg | Varies widely by purity and source |
| Research-grade (1mg vial) | $50–$120 per vial | Third-party purity verification essential |
| Monthly cycle cost | $150–$500+ | Depends on dose and cycle length |
The bottom line
IGF-1 LR3 is a anabolic compound with research interest in muscle growth, igf-1, recovery, body composition. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying anabolic processes and muscle development
- • Individuals interested in muscle growth under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Francis GL, Ross M, Ballard FJ, et al.. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol (1992). PMID: 1382112
- [2] Tomas FM, Knowles SE, Owens PC, et al.. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J (1993). PMID: 7680397
- [3] Clemmons DR.. Role of IGF-binding proteins in regulating IGF responses to changes in metabolism. J Mol Endocrinol (2018). doi: 10.1530/JME-18-0016 PMID: 29563157
- [4] Pollak M.. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008). doi: 10.1038/nrc2536 PMID: 19029956
- [5] Barton ER.. The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl Physiol Nutr Metab (2006). doi: 10.1139/h06-054 PMID: 17111008